全文获取类型
收费全文 | 4432篇 |
免费 | 489篇 |
国内免费 | 248篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 89篇 |
妇产科学 | 11篇 |
基础医学 | 118篇 |
口腔科学 | 9篇 |
临床医学 | 146篇 |
内科学 | 268篇 |
皮肤病学 | 92篇 |
神经病学 | 39篇 |
特种医学 | 100篇 |
外国民族医学 | 2篇 |
外科学 | 421篇 |
综合类 | 708篇 |
预防医学 | 89篇 |
眼科学 | 32篇 |
药学 | 2171篇 |
2篇 | |
中国医学 | 819篇 |
肿瘤学 | 51篇 |
出版年
2024年 | 10篇 |
2023年 | 48篇 |
2022年 | 89篇 |
2021年 | 127篇 |
2020年 | 91篇 |
2019年 | 86篇 |
2018年 | 98篇 |
2017年 | 147篇 |
2016年 | 181篇 |
2015年 | 183篇 |
2014年 | 450篇 |
2013年 | 417篇 |
2012年 | 368篇 |
2011年 | 366篇 |
2010年 | 261篇 |
2009年 | 246篇 |
2008年 | 269篇 |
2007年 | 329篇 |
2006年 | 284篇 |
2005年 | 246篇 |
2004年 | 201篇 |
2003年 | 158篇 |
2002年 | 141篇 |
2001年 | 107篇 |
2000年 | 88篇 |
1999年 | 57篇 |
1998年 | 30篇 |
1997年 | 20篇 |
1996年 | 9篇 |
1995年 | 15篇 |
1994年 | 3篇 |
1993年 | 5篇 |
1992年 | 4篇 |
1991年 | 5篇 |
1990年 | 4篇 |
1989年 | 3篇 |
1988年 | 7篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1984年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 1篇 |
排序方式: 共有5169条查询结果,搜索用时 15 毫秒
1.
《中国现代医生》2020,58(36):103-106+110
目的 对复方倍他米松注射液联合泛昔洛韦胶囊、普瑞巴林胶囊治疗带状疱疹的临床疗效进行观察并探讨。方法 选取2018 年1 月~2019 年12 月我院收治的118 例带状疱疹患者为研究对象,采用随机抽签的方式将患者分为对照组(泛昔洛韦胶囊+普瑞巴林胶囊+甲钴胺片+维生素B1 片)与观察组(联合复方倍他米松注射液),比较两组治疗总有效率、VAS 评分、QS 评分、C 反应蛋白、无新发皮疹时间、结痂时间及疼痛停止时间、随访2 个月后带状疱疹后遗神经痛发生率以及不良反应发生率。结果 观察组与对照组治疗总有效率分别为94.92%及76.27%,组间对比差异有统计学意义(P<0.05);治疗后,观察组VAS 评分显著低于对照组;观察组QS 评分低于对照组(P<0.05);治疗后,观察组C 反应蛋白显著低于对照组(P<0.05);观察组无新发皮疹时间、结痂时间及疼痛停止时间分别显著短于对照组(P<0.05);随访2 个月后,发现观察组带状疱疹后遗神经痛发生率显著低于对照组(P<0.05);观察组不良反应发生与对照组比较,差异无统计学意义(P>0.05)。结论 复方倍他米松注射液联合泛昔洛韦胶囊、普瑞巴林胶囊治疗带状疱疹不仅效果好且安全性高,值得使用。 相似文献
2.
《European journal of surgical oncology》2021,47(12):3105-3112
BackgroundDetails of perioperative outcomes and survival after gastric cancer surgery in prior transplant recipients have received minimal research attention.MethodsWe performed an observational cohort study using the database of 20,147 gastric cancer patients who underwent gastrectomy at a single gastric cancer center in Korea. Forty-one solid organ recipients [kidney (n = 35), liver (n = 5), or heart (n = 1)] were matched with 205 controls using propensity score matching.ResultsOperation time, blood loss, and postoperative pain were similar between groups. Short-term complication rates were similar between transplantation and control groups (22.0% vs. 20.1%, P = 0.777). Transplantation group patients with stage 1 gastric cancer experienced no recurrence, while those with stage 2/3 cancer had significantly higher recurrence risk compared to the controls (P = 0.049). For patients with stage 1 cancer, the transplantation group had a significantly higher rate of non-gastric cancer-related deaths compared to the controls (19.2% vs. 1.4%, P = 0.001). For those with stage 2/3 cancer, significantly lower proportion of the transplantation group received adjuvant chemotherapy compared to the control group (26.7% vs. 80.3%, P < 0.001). The transplantation group had a higher (albeit not statistically significant) rate of gastric cancer-related deaths compared to the controls (40.0% vs. 18.0%, P = 0.087).ConclusionTransplant recipients and non-transplant recipients exhibited similar perioperative and short-term outcomes after gastric cancer surgery. From long-term outcome analyses, we suggest active surveillance for non-gastric cancer-related deaths in patients with early gastric cancer, as well as strict oncologic care in patients with advanced cancer, as effective strategies for transplant recipients. 相似文献
3.
目的:通过郁乐疏胶囊与百忧解治疗卒中后抑郁(PSD)的随机对照研究,观察郁乐疏胶囊治疗PSD的疗效和安全性。方法:将40例PSD患者在使用治疗脑卒中基础疾病的药物的同时,随机分为受试药物组(郁乐疏胶囊组)和对照药物组(百忧解组)。前者口服郁乐疏胶囊,后者口服百忧解。两组患者在治疗前及治疗后6周各进行一次HRSD量表、Zung抑郁自评量表、Barthel量表及SNSS量表评定,并观察不良反应。结果:郁乐疏胶囊组,显效率为55%,总有效率为85%。百忧解组,显效率为50%,总有效率为80%。两组药物的疗效无显著差异(P>0.05)。两组患者在治疗前后,各量表评定均无显著差异(P>0.05)。但两组患者HRSD量表中的睡眠障碍因子的评分在治疗前无显著差异(P>0.05),在治疗后有显著差异(P<0.05)。结论:郁乐疏胶囊能明显改善PSD患者的抑郁症状,促进神经功能的恢复,同时还具有改善睡眠障碍的作用。无明显不良反应,安全性较高。 相似文献
4.
5.
GC法测定金银三七胶囊中的冰片的含量 总被引:1,自引:0,他引:1
目的:建立金银三七胶囊中冰片的含量测定方法。方法:采用GC法,色谱柱为10%PEG-20M;FID氢火焰检测器:柱温为115℃。结果:冰片在0.02559-0.5118μg范围内线性良好。加样回收率为99.9%,RSD%为1.94%(n=9)。结论:方法简便,可行,重现性良好,结果准确,可加强金银三七胶囊的质量控制。 相似文献
6.
复方华蟾胶囊抗小鼠肿中瘤作用的实验研究 总被引:2,自引:0,他引:2
目的了解复方华蟾胶囊抗小鼠移植性肿瘤的作用.方法以小鼠肝癌22(H22)、小鼠肉瘤180(S180)为瘤株,应用动物移植性肿瘤的体内试验法对药物进行抗癌药效学试验.结果复方华蟾胶囊灌胃4,2 g/kg@d,连续14 d,对小鼠移植性肝癌实体型生长有明显的抑制作用,抑瘤率分别为38.09%,30.95%.对小鼠移植性S180实体型生长有明显的抑制作用,抑瘤率分别为34.7%,30.08%.复方华蟾胶囊对荷瘤小鼠的胸腺和脾脏重量无影响.结论复方华蟾胶囊在试验条件下有一定抗肿瘤作用. 相似文献
7.
Cytochrome P450 3A4 and P-glycoprotein Activity and Assimilation of Tacrolimus in Transplant Patients with Persistent Diarrhea 总被引:2,自引:0,他引:2
Wim Lemahieu Bart Maes Kristin Verbeke Paul Rutgeerts Karel Geboes Yves Vanrenterghem 《American journal of transplantation》2005,5(6):1383-1391
Renal transplant recipients suffering from persistent diarrhea have been repeatedly reported to have increased tacrolimus (Tac) trough levels. This study aimed to explore this phenomenon in detail in 15 renal transplant recipients with diarrhea, whose immunosuppression consisted of corticosteroids, mofetil mycophenolate and Tac. Both hepatic and intestinal CYP3A4 and PGP activity, important determinants of Tac bioavailability, were assessed, together with global CYP activity and investigations for gastrointestinal infection, function and morphology. Global CYP, CYP3A4, PGP and trough/dose levels of Tac were compared with diarrhea-free controls. In addition, a pharmacokinetic study of Tac was performed in 11 patients affected by diarrhea versus 9 controls. As expected, diarrhea was associated with increased Tac trough levels. An even stronger, significant increase of dose-normalized Tac levels was observed between 90 and 360 min after Tac intake. Time to peak concentration and drug half-life, however, were not altered. In addition, a concomitant decrease (+/-50%) of intestinal PGP activity was noticed in patients with diarrhea. For global CYP, CYP3A4 and hepatic PGP activity no such differences were noted. This pattern was not influenced by the specific cause of diarrhea. These data strongly suggest that persistent diarrhea is associated with an increased oral bioavailability of Tac. 相似文献
8.
Y. Le Meur M. Büchler A. Thierry S. Caillard F. Villemain S. Lavaud I. Etienne P.-F. Westeel B. H. de Ligny L. Rostaing E. Thervet J. C. Szelag J.-P. Rérolle A. Rousseau G. Touchard P. Marquet 《American journal of transplantation》2007,7(11):2496-2503
Efficacy and safety of mycophenolate mofetil (MMF) may be optimized with individualized doses based on therapeutic monitoring of its active metabolite, mycophenolic acid (MPA). In this 12-month study, 137 renal allograft recipients from 11 French centers receiving basiliximab, cyclosporine A, MMF and corticosteroids were randomized to receive either concentration-controlled doses or fixed-dose MMF. A novel Bayesian estimator of MPA AUC based on three-point sampling was used to individualize doses on posttransplant days 7 and 14 and months 1, 3 and 6. The primary endpoint was treatment failure (death, graft loss, acute rejection and MMF discontinuation). Data from 65 patients/group were analyzed. At month 12, the concentration-controlled group had fewer treatment failures (p = 0.03) and acute rejection episodes (p = 0.01) with no differences in adverse event frequency. The MMF dose was higher in the concentration-controlled group at day 14 (p < 0.0001), month 1 (p < 0.0001) and month 3 (p < 0.01), as were median AUCs on day 14 (33.7 vs. 27.1 mg*h/L; p = 0.0001) and at month 1 (45.0 vs. 30.9 mg*h/L; p < 0.0001). Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events. 相似文献
9.
10.